Anteotech Ltd (ASX: ADO) announced Q3 FY22 business update

Anteotech Ltd (ASX: ADO) has released its quarterly activities reports for the quarter ended 31 March 2022.

• The company has contracted Clinical Research Organisation (CRO) in Spain to conduct prospective clinical trials for COVID19 RAT - to support TGA and EU Common List registrations
• In March, AnteoTech received correspondence from the UK Medicines & Healthcare products Regulatory Agency in relation to the submission for the EuGeni Covid-19 RAT approval.
• Continued technical progress with collaborators with results indicating that AnteoX binder formulation improved the test battery's cycle life by up to 100% at 70% capacity retention.
• Mr Pierre Nathie was appointed as Head of Products and Services to co-ordinate the Company’s R&D, Manufacturing, Quality Control, Regulatory assessments and to interface with the Sales and Marketing team.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au